Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

[MT 6314] Pharmacology & Toxicology > [3S] Protein Synthesis Inhibitors > Flashcards

[3S] Protein Synthesis Inhibitors Flashcards

1
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Widely distributed to all tissues including the CNS/CSF and placenta

A

Chloramphenicol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Chloramphenicol excretion

A

Renal; partly bile and feces

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Chloramphenicol ROA

A

IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA

● Binds to 50S
● Inhibits peptide bond formation
● Drug interactions: Phenytoin, Tolbutamide, Chlorpropamide, Warfarin

A

Chloramphenicol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Bacteriostatic
● Gr(+) aerobes
● Gr(+) anaerobes
● Gr(-) aerobes
● Gr(-) anaerobes
● Rickettsiae

A

Chloramphenicol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Especially effective against:
● H. influenzae
● N. meningitidis
● Bacteroides

A

Chloramphenicol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Inactive: Chlamydia

A

Chloramphenicol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

GI disturbances & Oral or Vaginal Candidiasis

A

Chloramphenicol Tetracycline & Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Bone marrow: Inhibition of red cell maturation
● Aplastic anemia
● Gray Baby Syndrome

A

Chloramphenicol

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Absorption is affected by food

A

Tetracycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Tetracycline excretion

A

Renal & Biliary

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Tetracycline ROA

A

PO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA

● Bacteriostatic
● Bind to 30S
● Inhibits binding of aminoacyl-tRNA to the acceptor site
● Intracellular concentration

A

ALL Tetracyclines

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

H. pylori ulcers

A

Tetracycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Gram-positive and gram- negative + anaerobes
● Chlamydiae
● Mycoplasma pneumoniae
● Borrelia, spirochetes, Anaplasma phagocytophilum, Ehrlichia sp.

A

Tetracycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Mainly for ricketssiae (Rocky mountain spotted fever) and borrelia (Lyme disease)

A

Tetracycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Alters intestinal flora
● Esophageal ulceration
● Enterocolitis

A

Tetracycline & Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Bacterial superinfections (S. aureus, C. difficile)
● Bones and teeth damage: Enamel dysplasia Crown
deformation
● Hepatic toxicity
● Renal toxicity

A

Tetracyclin, Doxycycline & Demeclocycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Fanconi Syndrome

A

Tetracycline & Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Renal tubular acidosis
● Nephrotoxicity
● Exacerbate pre-existing renal dysfunction

A

Tetracycline & Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Absorption is not affected by food

A

Doxycycline & Minocycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Doxycycline ROA

A

PO/IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Lyme disease

A

Tetracycline & Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Malaria prophylaxis

A

Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Amoebiasis

A

Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
26
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Primary & secondary syphilis (penicillin allergy)

A

Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
27
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Vestibulotoxicity

A

Doxycycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
28
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Demeclocycline excretion

A

Biliary & renally

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
29
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Demeclocycline ROA

A

PO

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
30
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Off-label treatment for inappropriate secretion of antidiuretic hormones

A

Demeclocycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
31
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

ADH-secreting tumors

A

Demeclocycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
32
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Photosensitivity (UV Light)

A

Demeclocycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
33
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Minocycline excretion

A

Mostly fecal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
34
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Minocycline ROA

A

PO/IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
35
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Meningococcal carrier state

A

Minocycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
36
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS: Minocycline

____________ is preferred due to resistant cases

A

ciprofloxacin/rifampin

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
37
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Vestibular toxicity
● Exacerbate pre-existing renal dysfunction

A

Minocycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
38
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Tigecycline excretion

A

Nonrenal (biliary)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
39
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Longest half-life

A

Tigecycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
40
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● MDR organisms
● Treats skin and skin-structure infections, intra- abdominal infections and CAP

A

Tigecycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
41
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Tigecycline ROA

A

IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
42
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Gr(+)
o CoNS, MRSA, VRE, Strep, Enterococci,
● Gr(-)
o Enterobacteriaceae, MDR Acinetobacter, Chlamydia, L. pneumophilia

A

Tigecycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
43
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Anaerobes, ricketssiae, mycobacteria

A

Tigecycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
44
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

INACTIVE AGAINST: Proteus, Providencia, Pseudomonas

A

Tigecycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
45
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Nausea
● Significantly higher mortality rates

A

Tigecycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
46
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Eravacycline excretion

A

Bile & urine + feces (10-40%)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
47
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Eravacycline ROA

A

IV

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
48
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● MDR organisms
● Complicated intra-abdominal infections
● Tigecycline uses

A

Eravacycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
49
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

NOT effective against UTI

A

Eravacycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
50
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Tetracycline toxicities + dose adjusted if used alongside CYP3A inducers like rifampin

A

Eravacycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
51
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Omadacycline excretion

A

Bile

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
52
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Administered 4 hours after as these may decrease
before or meals/supplements absorption

A

Omadacycline

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
53
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Omadacycline ROA

54
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Unaffected by most common resistance mechanisms

A

Omadacycline

55
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Can treat bacterial pneumonia and acute bacterial skin/skin- structure infections
● Tigecycline uses

A

Omadacycline

56
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Tetracycline toxicities + Rarer esophageal ulcerations

A

Omadacycline

57
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Streptomyces erythraea

A

Macrolides: Erthryomycin

58
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Erythromycin excretion

A

Biliary; partly renal

59
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Food interferes with absorption

A

Macrolides: Erthryomycin

60
Q

Erthryomycin ROA

61
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

50S inhibitor; inhibits peptide bond formation

A

Macrolides: Erthryomycin & Fidaxomicin

62
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Prototype drug

A

Macrolides: Erthryomycin

63
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● GR(+)
o pneumococci, strep, staph, corynebacteria, Mycoplasma, Legionella, Chlamydia, H. pylori, Listeria, Mycobacteria
● GR(-)
o Bordetella, Rickettsia, Campylobacter

A

Macrolides: Erthryomycin

64
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Corynebacterial
o sepsis, erythrasma
● Neisseria, Bartonella, Treponema, diphtheria,
● CAP
o Mycoplasma, Legionella, Pneumococci

A

Macrolides: Erthryomycin

65
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Prophylaxis : dental endocarditis

A

Macrolides: Erthryomycin

66
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Off-label : Gastroparesis

A

Macrolides: Erthryomycin

67
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Vestibular toxicity
● Exacerbate pre-existing renal dysfunction

A

Macrolides: Erthryomycin

68
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Clarithromycin excretion

A

Metabolized in the liver, partially excreted through urine

69
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Clarithromycin ROA

70
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA

● 50S inhibitor; inhibits peptide bond formation
● Also inhibits CYP3A4 and drug efflux pumps

A

Macrolides: Clarithromycin

71
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Mycobacterium avium complex
● M. leprosae
● T. gondii
● H. influenzae

A

Macrolides: Clarithromycin

72
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Similar toxicities and interactions as erythromycin
● Lower incidence gastrointestinal intolerance

A

Macrolides: Clarithromycin

73
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Torsades de pointes
● Arrhythmia

A

Macrolides: Clarithromycin & Azithromycin

74
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Azithromycin excretion

A

Bile & urine (remaining)

75
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Azithromycin ROA

76
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA

● 50S inhibitor; inhibits peptide bond formation
● 15-atom ring unlike the usual 14; cannot deactivate CYP450

A

Macrolides: Azithromycin

77
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Mycobacterium avium complex
● T. gondii
● H. influenzae
● Chlamydia sp.

A

Macrolides: Azithromycin

78
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Less active
● Staphylococci
● Streptococci

A

Macrolides: Azithromycin

79
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Possible increased risk of cardiac death

A

Macrolides: Azithromycin

80
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Fidaxomicin excretion

A

Feces & urine (remaining)

81
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Fidaxomicin ROA

82
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Clostridioides difficile
● Gr(+) aerobes
● Gr(-) anaerobes

A

Macrolides: Fidaxomicin

83
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Clindamycin excretion

A

Metabolized in the liver; excreted through bile & urine

84
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Clindamycin ROA

85
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Streptomyces lincolnensis

A

Lincosamide: Clindamycin

86
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Gr(+) cocci
● Streptococci & Staphylococci
o Skin and soft tissue infections

A

Lincosamide: Clindamycin

87
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Pneumococci, Bacteroides sp.
● Other anaerobes : Bacteroides, Fusobacterium, Prevotella
o Severe anaerobic infections

A

Lincosamide: Clindamycin

88
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Toxic shock syndrome (with penicillin G)
● Necrotizing fasciitis

A

Lincosamide: Clindamycin

89
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Wounds of the abdomen and gut (with ________ or __________)

A

cephalosporins or aminoglycosides ; Lincosamide: Clindamycin

90
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Female genital tract: Septic abortion, Pelvic abscesses, Pelvic inflammatory disease

A

Lincosamide: Clindamycin

91
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Lung and peritoneal abscesses
● Endocarditis prophylaxis (valvular disease)

A

Lincosamide: Clindamycin

92
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

AIDS:
o P. jiroveci pneumonia (with primaquine)
o Toxoplasmosis (with pyrimethane)

A

Lincosamide: Clindamycin

93
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● GI irritation
● Mainly diarrhea
● Skin rashes
● Neutropenia

A

Lincosamide: Clindamycin

94
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Hepatic dysfunction
● Pseudomembranous colitis (superinfections with C. difficile)

A

Lincosamide: Clindamycin

95
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

A

Ketolides: Telithromycin

96
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Telithromycin excretion

A

Metabolized in the liver and excreted through bile and urine

97
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Telithromycin ROA

98
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● CAP
● Macrolide-resistant bacteria

A

Ketolides: Telithromycin

99
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Hepatitis
● Liver failure
● Myasthenia gravis (contraindication)

A

Ketolides: Telithromycin

100
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● STIs
● macrolide-resistant bacteria

A

Ketolides: Solithromycin

101
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Adverse effects are inadequately observed

A

Ketolides: Solithromycin

102
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Solithromycin excretion

103
Q

MODERATE SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Solithromycin ROA

104
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Quinupristin-dalfopristin elimination

105
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Quinupristin-dalfopristin ROA

106
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA

● Rapidly bactericidal
● 50S inhibitor; inhibits peptide bond formation

A

Streptogramins: Quinupristin-dalfopristin

107
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

Gr(+)
o MDR strep, PRSP, methicillin-susceptible and resistant staph, E. faecium

A

Streptogramins: Quinupristin-dalfopristin

108
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Not rapidly bactericidal against E. faecium
● Not active against E. faecalis

A

Streptogramins: Quinupristin-dalfopristin

109
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Arthralgia-myalgia syndrome
● Pain at infusion site

A

Streptogramins: Quinupristin-Dalfopristin

110
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

CYP3A4 inhibitor - increases concentrations of warfarin, diazepam, quetiapine, simvastatin, and cyclosporine

A

Streptogramins: Quinupristin-Dalfopristin

111
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Linezolid elimination

112
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA

● 50S inhibitor; inhibits peptide bond formation
● Binds at the 23S ribosomal RNA of the 50S subunit

A

Oxazolidinones: Linezolid & Tedizolid

113
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● MRSA
● VRE
● HCAP
● CAP
● [Off-label] MDR-TB, Nocardia

A

Oxazolidinones: Linezolid

114
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Hematologic effects (thrombocytopenia, neutropenia, anemia)

A

Oxazolidinones: Linezolid

115
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Optic and peripheral neuropathy
● Lactic acidosis

A

Oxazolidinones: Linezolid

116
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Serotonin syndrome (with SSRIs)

A

Oxazolidinones: Linezolid

117
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Linezolid ROA

118
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Staphylococci - better than linezolid
● Skin and soft tissue infections

A

Oxazolidinones: Tedizolid

119
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Nausea, dizziness, diarrhea
● Lower risk of hematologic effects, bone marrow suppression, and serotonin syndrome

A

Oxazolidinones: Tedizolid

120
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Lefamulin excretion & metabolism

A

Feces, partly urine

121
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Lefamulin ROA

122
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Tedizolid ROA

123
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS PKINETICS

Tedizolid excretion

A

Feces & urine (remaining)

124
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS MOA

● Binds to 50S
● Prevents bacterial tRNA from binding appropriately by binding pocket

A

Pleuromutilins: Lefamulin

125
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

CAP pathogens
o Legionella, Mycoplasma, Chlamydophila

A

Pleuromutilins: Lefamulin

126
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

● Aerobic Gr (+)
o S. pyogenes, S. aureus, E. faecium
● STI
o M. genitalium, Neisseria, Chlamydia

A

Pleuromutilins: Lefamulin

127
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

NO ACTIVITY against E. faecalis
o Pseudomonas, Acinetobacter, Enterobacteriaceae

A

Pleuromutilins: Lefamulin

128
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

● Infusion-site reactions
● GI disturbances

A

Pleuromutilins: Lefamulin

129
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS TOXICITIES

Congenital malformations (contraindicated during pregnancy)

A

Pleuromutilins: Lefamulin

130
Q

BROAD SPECTRUM PROTEIN SYNTHESIS INHIBITORS

Doxycycline elimination

A

Nonrenally

131
Q

NARROW SPECTRUM PROTEIN SYNTHESIS INHIBITORS CLINICAL APPLICATIONS

High potency against Gr(+) bacteria
○ MRSA
○ VRE
○ Streptococci
○ Gr(+) anaerobesg

A

Oxazolidinones: Tedizolid

[MT 6314] Pharmacology & Toxicology (20 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions